Full history for every metric is available with a Kvantra account
iTeos Therapeutics, Inc. (ITOS)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 345 | 268 | 13 | 35 |
| Operating profit | $m | -160 | |||||
| Net profit | $m | -22 | -38 | 215 | 97 | -113 | -134 |
| EPS reported | $ | -3.32 | |||||
| Operating cashflow per share | $ | -2.43 | |||||
| Capex per share | $ | 0.04 | |||||
| FCF per share | $ | -2.47 | |||||
| Free cash flow | $m | -100 | |||||
| Net debt | $m | -495 | |||||
| Book value equity | $m | 590 | |||||
| Book value per share | $ | 14.58 | |||||
| Number of shares | m | 40.47 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 0.53 | |||||
| P/S LTM | x | 8.88 | |||||
| P/FCF LTM | x | -3.11 | |||||
| EV/EBITDA LTM | x | -1.43 | |||||
| EV/Sales LTM | x | 4.97 | |||||
| Earnings Yield LTM | % | -43.24% | |||||
| FCF Yield | % | -32.11% | |||||
| Quality | |||||||
| ROE | % | -22.77% | |||||
| ROIC | % | -24.62% | |||||
| Operating margin | % | -455.79% | |||||
| Gross margin | % | 96.46% | |||||
| FCF/Sales | % | -285.18% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +177.89% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -19.59 | |||||
| Net Debt/EBITDA | x | 1.12 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -159.13% | |||||
| Net debt/Equity | x | -0.84 | |||||
| Gross debt/equity | x | 0.01 | |||||
Company overview
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free